20 related articles for article (PubMed ID: 23643089)
1. P300/CBP-associated factor (PCAF) inhibits the growth of hepatocellular carcinoma by promoting cell autophagy.
Jia YL; Xu M; Dou CW; Liu ZK; Xue YM; Yao BW; Ding LL; Tu KS; Zheng X; Liu QG
Cell Death Dis; 2016 Oct; 7(10):e2400. PubMed ID: 27711074
[TBL] [Abstract][Full Text] [Related]
2. Histone acetyltransferase PCAF accelerates apoptosis by repressing a GLI1/BCL2/BAX axis in hepatocellular carcinoma.
Gai X; Tu K; Li C; Lu Z; Roberts LR; Zheng X
Cell Death Dis; 2015 Apr; 6(4):e1712. PubMed ID: 25855960
[TBL] [Abstract][Full Text] [Related]
3. Histone acetyltransferase PCAF up-regulated cell apoptosis in hepatocellular carcinoma via acetylating histone H4 and inactivating AKT signaling.
Zheng X; Gai X; Ding F; Lu Z; Tu K; Yao Y; Liu Q
Mol Cancer; 2013 Aug; 12(1):96. PubMed ID: 23981651
[TBL] [Abstract][Full Text] [Related]
4. The beta2-adrenergic receptor is a potential prognostic biomarker for human hepatocellular carcinoma after curative resection.
Chen D; Xing W; Hong J; Wang M; Huang Y; Zhu C; Yuan Y; Zeng W
Ann Surg Oncol; 2012 Oct; 19(11):3556-65. PubMed ID: 22588469
[TBL] [Abstract][Full Text] [Related]
5. Low expression of CD112 is associated with poor overall survival in patients with hepatocellular carcinoma.
Huang X; Qu P; Chen Y; Zhou X; Wu Y; Liu F; Wang D; Zhang J; An J
Hum Pathol; 2014 Sep; 45(9):1944-50. PubMed ID: 25081539
[TBL] [Abstract][Full Text] [Related]
6. Cytokeratin 10 and cytokeratin 19: predictive markers for poor prognosis in hepatocellular carcinoma patients after curative resection.
Yang XR; Xu Y; Shi GM; Fan J; Zhou J; Ji Y; Sun HC; Qiu SJ; Yu B; Gao Q; He YZ; Qin WZ; Chen RX; Yang GH; Wu B; Lu Q; Wu ZQ; Tang ZY
Clin Cancer Res; 2008 Jun; 14(12):3850-9. PubMed ID: 18559605
[TBL] [Abstract][Full Text] [Related]
7. [The expression and significance of heparanase and nm23-H1 in hepatocellular carcinoma].
Liu Y; Chen X; Peng S; Fang H; Wu Y; Peng C; Shi L; Bai M; Xu B; Wang J; Deng G
Zhonghua Yi Xue Za Zhi; 2002 Nov; 82(22):1553-6. PubMed ID: 12609066
[TBL] [Abstract][Full Text] [Related]
8. [Expression and clinical significance of coagulate and fibrolysis factors in tissue and plasma from hepatocellular carcinoma patients].
Zhou Q; Liang LJ; Peng BG; Zhen YY
Ai Zheng; 2006 Nov; 25(11):1433-8. PubMed ID: 17094916
[TBL] [Abstract][Full Text] [Related]
9. PCAF fine-tunes hepatic metabolic syndrome, inflammatory disease, and cancer.
Wang T; Yao W; Shao Y; Zheng R; Huang F
J Cell Mol Med; 2018 Dec; 22(12):5787-5800. PubMed ID: 30216660
[TBL] [Abstract][Full Text] [Related]
10. [Expression of PCAF in hepatocellular carcinoma and its clinical significance].
Tuo H; Zheng X; Tu K; Zhou Z; Yao Y; Liu Q
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Mar; 29(3):297-300. PubMed ID: 23643089
[TBL] [Abstract][Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
